Services

Blood Vessels Find Tender

📄 Tender ID: 539875027 📅 Published: 05 Nov 2026

📋 Tender Overview

Researchers at the Max Planck Institute for Molecular Biomedicine and CNIC Madrid have discovered how blood vessels can grow even when the key VEGF-VEGFR2 pathway is blocked. Using a novel genetic mosaic technology, they found that endothelial cells reprogram into venous-like cells - a process called venous reprogramming. This adaptation and resistance mechanisms may explain why anti-cancer drugs inhibiting vascular growth often fail long-term. The findings open new avenues for combination therapies that block multiple pathways simultaneously. The study is published in Nature. Nov 4, 2026, 6:59:36 PM Dr. Jeanine Muller-Keuker , Max-Planck-Institut fur molekulare Biomedizin In cancer research, anti-angiogenic drugs are used with the aim to block blood vessel growth (angiogenesis) in order to inhibit the tumor growth and metastasis. However, tumors develop resistance to these therapies over time - a major problem in cancer treatment.Researchers at the Max Planck Institute for Molecular Biomedicine and the Centro Nacional de Investigaciones Cardiovasculares (CNIC) in Madrid have now demonstrated in a study published in Nature that: When the classic VEGF-VEGFR2 signalling pathway is blocked, endothelial cells - which line the inside of blood vessels - adapt: they change their identity and become venous cells that grow independently of VEGF. This process, known as venous genetic reprogramming, enables vessels without VEGF signalling to grow inside organs and tumors.How the researchers made this discoveryUntil now, the signaling provided by the vascular endothelial growth factor (VEGF) and its receptor VEGFR2 was considered essential for the formation of new blood vessels--especially in tumors. That is why many cancer drugs aim to block this pathway. However, in many patients, resistance develops over time and the tumor continues to grow.To understand how blood vessels can survive and grow despite the blockade of the VEGFR2 pathway, the research team developed a novel genetic mosaic technique-- a method which, for the first time, makes it possible to compare healthy vascular cells and those lacking VEGFR2 signalling directly within the same organism and tumor. In this approach, both cell types grow side by side, are labeled with different colors, and can be tracked over long periods of time--from embryonic development through adulthood.The method was developed by the team of Rui Benedito and enables an unprecedented level of resolution in functional genetics: We can now very precisely analyze and quantify how mutated cells behave compared to normal cells over long periods of time, explains Rui Benedito. This revealed that over time certain mutant cells become prevalent in veins and small blood vessels, and continue to grow and proliferate despite the complete absence of VEGF-VEGFR2 signaling.The surprise: Cells change their identityThe key discovery: The vascular cells that lost the VEGFR2 pathway altered their genetic makeup over time. They adapted and transformed into venous cells--a process the researchers call venousization or venous reprogramming. This genetic reprogramming was crucial for the mutant cells survival and their ability to form new blood vessels.In addition, two other receptors--VEGFR1 and VEGFR3--played also a supporting role. They helped the cells move and survive when the main VEGF-VEGFR2 pathway was missing.Why this may be important for people with cancerThe findings explain why anti-angiogenesis drugs used in cancer, that block only the VEGF-VEGFR2 pathway, often have only a temporary effect. When only one pathway is targeted for long periods of time, vascular cells have time to adapt and find alternative ways of growing. This is natural selection in action, with the fittest cells eventually becoming dominant, says Dr. Rui Benedito, who has been working at the Max Planck Institute for Molecular Biomedicine in Munster since June 2025 and led the study. If we block just one pathway, the cells find another. To achieve a lasting effect, we must block multiple pathways simultaneously.The Future: New Therapies Through CombinationThe identification of how blood vessels can grow in the absence of VEGF signalling offers new hope: Future anti-angiogenesis and anti-cancer therapies could block several of these pathways at the same time--for example, through combinations of drugs that block VEGF-VEGFR2 signalling and the molecules responsible for the identified venous reprogramming.We now have a much better understanding of the alternative venous growth pathways, and so we can aim to specifically block them, says Benedito. We expect the combination targeting to be much more effective.Background: Research at the Max Planck Institute for Molecular BiomedicineThe study was conducted at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) in Madrid, where Rui Benedito served as head of the Molecular Genetics of Angiogenesis group. Since June 2025, he has been working at the Max Planck Institute for Molecular Biomedicine in Munster, where he continues to study the mechanisms of blood vessel development (angiogenesis) in physiological and disease models.His team is using advanced single cell genetic tools to investigate how cells forming blood vessels grow and adapt to changes--with the goal of developing new therapies for cancer, cardiovascular diseases, and other conditions.The research was supported by the European Research Council (ERC), the Spanish Ministry of Science, the la Caixa Foundation and the Max Planck Institute for Molecular Biomedicine. Original Publication: Irene Garcia-Gonzalez, Susana F. Rocha, Filipa V. Oliveira, Maria S. Sanchez-Munoz, MariyaLytvyn, Aroa Garcia-Cabero, Ute Ipe, Mariona Graupera,,Taija Makinen, Rui Benedito.Venousization enables angiogenesis in the absence of VEGFR signalingNature, Nov. 04, 2026DOI: 10.1038/s41586-026-11224-w Source: https://idw-online.de/de/news880244

🔍 Key Information

📄
Tender Reference No.
539875027
📅
Publication Date
05 Nov 2026
🌐
Sector
Services
📝
Notice Type
News
📍
Location
Germany

📁 Documents & Downloads

No documents found

🏷️ CPV

No CPV found

Need help with this bid?

Our bid experts can help you find, evaluate & win more tenders.

🎧 Talk to Bid Expert
🕒 Submission deadline
0
days remaining · 05 Nov 2026
🔔 Set Alert

🧭 Quick Facts

Authority N/A
Country Germany
State / UT N/A
Tender Type Procurement News
Currency N/A
Similar Tenders
Loading similar tenders…